ストックスクリーナーアプリを入手
0.8209
7.13%
-0.063
Coherus Oncology Inc (CHRS) 最新ニュース
Coherus Oncology 2025 Q2 Earnings Strong Turnaround with 2404.5% Net Income Surge - AInvest
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Coherus BioSciences Q2 2025 misses EPS, stock dips - Investing.com Canada
Coherus Oncology Inc (CHRS) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Coherus (CHRS) Q2 Revenue Jumps 10% - AOL.com
Coherus Oncology Reports Strong Q2 2025 Growth - TipRanks
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 - 富途牛牛
Coherus Oncology (CHRS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Coherus Oncology: Q2 Earnings Snapshot - San Antonio Express-News
Coherus Oncology Q2 2025: LOQTORZI revenue up 36% to $10.0mln. - AInvest
Coherus Oncology Reports Second Quarter 2025 Financial Results a - GuruFocus
Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update - GlobeNewswire
Coherus Oncology, Inc. (NASDAQ:CHRS) is largely controlled by institutional shareholders who own 54% of the company - Yahoo Finance
What is Coherus BioSciences Inc. company’s growth strategyLightning-fast capital gains - Jammu Links News
Earnings Preview: CHRS to Report Financial Results Post-market on August 07 - 富途牛牛
Coherus Oncology to Report Second Quarter 2025 Financial Results on August 7, 2025 | CHRS Stock News - GuruFocus
Coherus Oncology to Release Second Quarter 2025 Financial Results on August 7, 2025 - Quiver Quantitative
Coherus Earnings: Q2 2025 Results and Management Call Set for August 7 After Market Close - Stock Titan
Why Coherus BioSciences Inc. stock attracts strong analyst attentionHigh Reward Risk Balanced Trading - metal.it
Coherus Oncology, Inc.'s (NASDAQ:CHRS) Price Is Right But Growth Is Lacking After Shares Rocket 35% - simplywall.st
Positive week for Coherus Oncology, Inc. (NASDAQ:CHRS) institutional investors who lost 47% over the past year - simplywall.st
Alvotech: A Fast Expanding Biosimilar Concern (NASDAQ:ALVO) - Seeking Alpha
Coherus BioSciences, Inc. (NASDAQ:CHRS) Analysts Are Reducing Their Forecasts For This Year - 富途牛牛
Coherus Biosciences Receives Nasdaq Deficiency Notice - TipRanks
Strength Seen in Krystal Biotech (KRYS): Can Its 4.2% Jump Turn into More Strength? - Nasdaq
Coherus Oncology reports annual meeting results By Investing.com - Investing.com Canada
Coherus Oncology reports annual meeting results - Investing.com
Coherus Biosciences Holds Virtual Annual Stockholder Meeting - TipRanks
Coherus BioSciences, Inc. (CHRS): A Bull Case Theory - Insider Monkey
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus - Investing.com
Coherus at Jefferies Conference: Strategic Growth and Pipeline Focus By Investing.com - Investing.com Canada
Coherus BioSciences Renames to Coherus Oncology, Focusing on Cancer Treatments. - AInvest
Genocea Biosciences (NASDAQ:GNCAQ) vs. Coherus BioSciences (NASDAQ:CHRS) Critical Survey - Defense World
Coherus Oncology (CHRS) Shifts Focus with New Name and Innovativ - GuruFocus
Coherus Biosciences Rebrands to Coherus Oncology - TipRanks
Coherus Completes Strategic Transformation to Coherus Oncology, - GuruFocus
Coherus Completes Strategic Transformation to Coherus Oncology, Focusing Exclusively on Innovative Cancer Therapeutics | CHRS Stock News - GuruFocus
Coherus Completes Strategic Transformation To Coherus Oncology - marketscreener.com
Coherus Completes Strategic Transformation to Coherus - GlobeNewswire
Coherus Makes Bold Strategic Shift: Rebrands as Cancer-Focused Powerhouse with 3 Novel Immunotherapies - Stock Titan
Coherus Oncology shares rise 5.13% after-hours following strategic transformation and pipeline updates. - AInvest
First patient dosed in STORM-Coherus cancer alliance - Business Weekly
Coherus BioSciences at 6th Annual Oncology Summit: Strategic Shift to Innovation - Investing.com Canada
Coherus BioSciences, Inc. Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI®? (toripalimab-Ttzi) - marketscreener.com
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Colla - GuruFocus
Coherus BioSciences (CHRS) Engages in New Cancer Treatment Collaboration | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) | CHRS Stock News - GuruFocus
Coherus Announces Clinical Collaboration with STORM Therapeutics to Evaluate STC-15 in Combination with LOQTORZI® (toripalimab-tpzi) - The Manila Times
Coherus Announces Clinical Collaboration with STORM - GlobeNewswire
Breakthrough Cancer Trial Launches: LOQTORZI Combination Study Targets 4 Major Cancer Types - Stock Titan
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles By Investing.com - Investing.com Canada
Coherus BioSciences’ SWOT analysis: promising pipeline faces clinical hurdles - Investing.com
StockNews.com Downgrades Coherus BioSciences (NASDAQ:CHRS) to Sell - Defense World
The Manufacturers Life Insurance Company Takes Position in Coherus BioSciences, Inc. (NASDAQ:CHRS) - Defense World
0.24%
3.39%
大文字化:
|
ボリューム (24 時間):